Similarly, for metastatic NSCLC, the median overall survival time of the atezolizumab treatment group reached 20.2 months (HR = 0.59) with the highest PD-L1 expression(Herbst et al. 2020). This evidence concerns the gene CD274 and non-small cell lung carcinoma.